BPC-157 and Thymosin Beta-4 in Nervous System Research: Brain Injury, Stroke, Spinal Cord and Nerve Models

RESEARCH · BPC-157 + TB-500 · NERVOUS SYSTEM MODELS

BPC-157 and Thymosin Beta-4 in Nervous System Research: Brain Injury, Stroke, Spinal Cord and Nerve Models

PurixLab’s BPC-157 + TB-500 10mg is a research vial combining a pentadecapeptide and a thymosin beta-4 fragment. Our earlier articles cover the blend composition, the preclinical evidence and the human data gap, proposed molecular mechanisms and tendon, ligament and muscle injury models. This article turns to the nervous system: brain trauma, stroke-like ischaemia, spinal cord compression, peripheral nerve injury, demyelination and neurotransmitter models. Almost all of it is rodent work. The vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Two literatures, not one

The nervous system data for the two components come from separate research programmes that have never been combined. BPC-157 studies come overwhelmingly from one Zagreb-based group, whose 2022 review grouped stroke, catalepsy, schizophrenia-like behaviour and spinal cord compression models under a single explanation built on nitric oxide and dopamine systems [1]. The thymosin beta-4 (Tβ4) studies come mostly from a Detroit-based group working on stroke, brain trauma, demyelination and diabetic neuropathy; their 2015 editorial proposed oligodendrogenesis, the generation of myelin-forming cells, as a common link and suggested that altered microRNA expression may mediate it [2]. We found no published study testing the two peptides together in any nervous system model.

A second caveat concerns identity. The Tβ4 papers below used the full-length peptide, which the stroke paper describes as a 43-amino acid protein that sequesters G-actin monomers [3]. “TB-500” is a trade name: when a product sold as TB-500 was analysed by high-resolution mass spectrometry, the analysts identified the N-terminal acetylated 17-23 fragment of Tβ4 (Ac-LKKTETQ) [4]. Results for full-length Tβ4 cannot automatically be transferred to a fragment.

BPC-157: brain injury and ischaemia

In a falling-weight traumatic brain injury model in mice, BPC-157 given shortly before injury was reported to improve the ratio of conscious, unconscious and dead animals across a range of impact forces, with less intense haemorrhagic lesions and less brain oedema over the 24 h after injury [5].

A rat stroke-like model used bilateral clamping of the common carotid arteries for 20 minutes, followed by reperfusion. BPC-157 was applied as a bath to the operated area, and the authors reported that early and delayed hippocampal neuronal damage was counteracted, with recovery in the Morris water maze, beam-walking and lateral push tests at 24 and 72 hr. Hippocampal gene expression changes included increased Vegfr2, Nos3 and Nos1 and decreased Nos2 and Nfkb [6]. The cuprizone model, a toxic demyelination model used in multiple sclerosis research, was combined in another study with a colitis model; BPC-157 rats had less nerve damage in the corpus callosum, thalamus and motor neurons and less cerebellar ataxia [7].

BPC-157: spinal cord and peripheral nerve

In the spinal cord model, the sacrocaudal cord was compressed after laminectomy, producing tail paralysis. Rats given a single intraperitoneal administration 10 min after injury were followed for up to 360 days; treated rats showed better tail motor function, no autotomy and resolved spasticity by day 15, with fewer vacuoles, less axon and motoneuron loss and less oedema on histology [8]. A follow-up from the same group described the first minutes after a 1 min compression and also treatment started at day 4, when tail paralysis was already established, reporting recovery of tail function and no demyelination on Luxol fast blue staining [9].

For the peripheral nervous system, a rat sciatic nerve transection study compared several routes and a nerve tube bridging a 7 mm gap. Treated rats showed faster axonal regeneration, larger motor action potentials and a better sciatic functional index [10].

BPC-157: neurotransmitter and behaviour models

A different strand looks at monoamine systems. Using alpha-[14C]methyl-L-tryptophan autoradiography, a three-author study measured regional serotonin synthesis in rat brain and found region-specific decreases and increases after single and 7-day treatment, with the authors stating that the data could not determine the mechanism [11]. In a rat serotonin syndrome model produced by pargyline plus L-tryptophan, BPC-157 counteracted signs such as hyperthermia and wet dog shakes [12]. Older mouse work reported reduced tremor, akinesia and catalepsy in MPTP and reserpine Parkinsonism models [13], and a 2021 rat study reported that BPC-157 counteracted amphetamine-, apomorphine- and MK-801-induced behaviours, haloperidol catalepsy and methamphetamine sensitisation, keeping its effect under nitric oxide synthase blockade [14].

Full-length thymosin beta-4: stroke, trauma, myelin and nerve

In rats with embolic middle cerebral artery occlusion, Tβ4 started 24 h after occlusion improved adhesive-removal and neurological severity scores without changing lesion volume, with more myelinated axons, more oligodendrocyte progenitor cells and higher vessel density at the ischaemic boundary [3]. In aged rats (18-21 months) the pattern reversed: Tβ4 reduced infarct volume by more than 50% compared with controls but did not improve functional outcome, myelination or gliosis [15].

After controlled cortical impact brain trauma in rats, Tβ4 started on day 1 did not change lesion volume but reduced hippocampal cell loss, increased angiogenesis, neurogenesis and oligodendrogenesis, and improved sensorimotor recovery and spatial learning [16]. When started 6 hours after injury, it also reduced cortical lesion volume, and the higher of two tested amounts gave better results [17]. In two mouse demyelination models, experimental autoimmune encephalomyelitis and cuprizone, Tβ4 increased new mature oligodendrocytes and remyelination with EGFR pathway involvement [18]. In type II diabetic mice with peripheral neuropathy, Tβ4 increased sciatic nerve blood flow and vascular density and improved nerve function, with angiopoietin-1 and PI3K/Akt signalling implicated [19].

Human evidence

We found no controlled human trial of BPC-157 or Tβ4 for a neurological outcome in a PubMed search on 24 October 2026. The closest item is a 2026 report of three inferior alveolar nerve injury cases managed with a multimodal approach that included peptide agents alongside dexamethasone and local anaesthetic; the authors state that spontaneous recovery and other confounders cannot be excluded, that causality cannot be established, and that the processes involved have been demonstrated mainly in preclinical models [20].

Reading this literature critically

  • Independence. Each peptide’s neurological data come largely from a single laboratory network [1,2]; independent replication is limited.
  • Age and model. Benefit on function in young rats did not carry over to aged rats [15].
  • Material. Full-length Tβ4 and a TB-500 fragment are different molecules [4], and no study has tested the blend.

What remains open

  • Whether any of the rodent findings reproduce in independent laboratories with blinded outcome assessment.
  • Whether BPC-157 or Tβ4 fragments reach brain or spinal cord tissue, and which analytical methods could confirm it.

BPC-157 + TB-500 10mg at PurixLab

BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg per vial (10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View BPC-157 + TB-500 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Vukojevic J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PubMed 34380875 · PMC8504390 · doi:10.4103/1673-5374.320969
  2. Chopp M, Zhang ZG. Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases. Expert Opin Biol Ther. 2015;15 Suppl 1:S9-12. PubMed 25613458 · doi:10.1517/14712598.2015.1005596
  3. Morris DC, Chopp M, Zhang L, et al. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-82. PubMed 20627173 · PMC2907184 · doi:10.1016/j.neuroscience.2010.05.017
  4. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
  5. Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept. 2010;160(1-3):26-32. PubMed 19931318 · doi:10.1016/j.regpep.2009.11.012
  6. Vukojević J, Vrdoljak B, Malekinušić D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. PubMed 32558293 · PMC7428500 · doi:10.1002/brb3.1726
  7. Klicek R, Kolenc D, Suran J, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013;64(5):597-612. PubMed 24304574
  8. Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019;14(1):199. PubMed 31266512 · PMC6604284 · doi:10.1186/s13018-019-1242-6
  9. Perovic D, Milavic M, Dokuzovic S, et al. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy. Curr Issues Mol Biol. 2022;44(5):1901-1927. PubMed 35678659 · PMC9164058 · doi:10.3390/cimb44050130
  10. Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41. PubMed 19903499 · doi:10.1016/j.regpep.2009.11.005
  11. Tohyama Y, Sikirić P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life Sci. 2004;76(3):345-57. PubMed 15531385 · doi:10.1016/j.lfs.2004.08.010
  12. Boban Blagaic A, Blagaic V, Mirt M, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512(2-3):173-9. PubMed 15840402 · doi:10.1016/j.ejphar.2005.02.033
  13. Sikiric P, Marovic A, Matoz W, et al. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol Paris. 1999;93(6):505-12. PubMed 10672997 · doi:10.1016/s0928-4257(99)00119-9
  14. Zemba Cilic A, Zemba M, Cilic M, et al. Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. Behav Brain Res. 2021;396:112919. PubMed 32956773 · doi:10.1016/j.bbr.2020.112919
  15. Morris DC, Cheung WL, Loi R, et al. Thymosin β4 for the treatment of acute stroke in aged rats. Neurosci Lett. 2017;659:7-13. PubMed 28864242 · PMC5624853 · doi:10.1016/j.neulet.2017.08.064
  16. Xiong Y, Mahmood A, Meng Y, et al. Treatment of traumatic brain injury with thymosin β₄ in rats. J Neurosurg. 2011;114(1):102-15. PubMed 20486893 · PMC2962722 · doi:10.3171/2010.4.JNS10118
  17. Xiong Y, Zhang Y, Mahmood A, et al. Neuroprotective and neurorestorative effects of thymosin β4 treatment initiated 6 hours after traumatic brain injury in rats. J Neurosurg. 2012;116(5):1081-92. PubMed 22324420 · PMC3392183 · doi:10.3171/2012.1.JNS111729
  18. Zhang J, Zhang ZG, Li Y, et al. Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system. Neurobiol Dis. 2016;88:85-95. PubMed 26805386 · doi:10.1016/j.nbd.2016.01.010
  19. Wang L, Chopp M, Szalad A, et al. Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice. Neurobiol Dis. 2012;48(3):546-55. PubMed 22922221 · PMC3533234 · doi:10.1016/j.nbd.2012.08.002
  20. Froum S, Estrin N, Pico G, et al. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health. 2026;7:1907109. PubMed 42876687 · PMC13661421 · doi:10.3389/froh.2026.1907109

Leave a Comment

Your email address will not be published. Required fields are marked *